Defendant
9 cases as defendant.
Fourth Jazz Complaint re-asserting U.S. 8,731,963 after FDA required Avadel to file a Paragraph IV certification. Avadel counterclaimed for non-infringement, invalidity, delisting, and Sherman Act monopolization. The case was dismissed by stipulation on March 7, 2023.
Fourth Jazz complaint/antitrust case involving Jazz's listing of the '963 (REMS) patent and Avadel's Sherman Act counterclaims. Jazz moved to stay pending final resolution of the validity of U.S. Patent No. 11,147,782. Dismissed with prejudice on October 27, 2025 pursuant to settlement.
Patent infringement action involving Jazz Pharmaceuticals entities and Avadel entities; resolved in the same October 2025 global settlement and stipulation of dismissal with prejudice entered October 27, 2025.
First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.
Jazz-side Delaware action in the Avadel–Jazz once-nightly sodium oxybate dispute. The '986 patent appeared on the patent lists in connection with Avadel's counterclaims and inequitable-conduct/derivation allegations concerning Flamel's '321 application and Jazz's '079/'782 patents. The case was resolved by the October 2025 settlement and dismissed with prejudice on 2025-10-27.
Lead Hatch-Waxman/Lumryz case reported for US 10,736,866; the case went to jury trial in 2024 and was terminated on 2025-10-27.
Patent infringement action by Jazz Pharmaceuticals against Avadel CNS Pharmaceuticals concerning sodium oxybate/LUMRYZ; consolidated with related actions and resolved by a global settlement and stipulation of dismissal with prejudice entered October 27, 2025.
DrugPatentWatch lists the '400 patent in this Avadel matter; the exact case number and whether the '400 patent was actually asserted could not be independently confirmed. It is listed as terminated Oct 27, 2025.
Lumryz/FT218 litigation; trial record identifies the '219 patent as a Jazz patent. Actively litigated in 2023; final judgment not confirmed.